Patents by Inventor Stefan Steidl
Stefan Steidl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132618Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.Type: ApplicationFiled: March 1, 2022Publication date: April 25, 2024Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
-
Publication number: 20240109977Abstract: The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).Type: ApplicationFiled: January 14, 2022Publication date: April 4, 2024Inventors: Stefan Steidl, Stefan Härtle, Rainer Boxhammer
-
Publication number: 20220144965Abstract: The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.Type: ApplicationFiled: March 13, 2020Publication date: May 12, 2022Inventors: Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
-
Publication number: 20210347879Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: May 7, 2021Publication date: November 11, 2021Inventors: Stefan STEIDL, Elisabeth THOMASSEN-WOLF
-
Patent number: 11028165Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: June 17, 2019Date of Patent: June 8, 2021Assignee: MORPHOSYS AGInventors: Stefan Steidl, Elisabeth Thomassen-Wolf
-
Publication number: 20210130451Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.Type: ApplicationFiled: January 8, 2021Publication date: May 6, 2021Applicant: MORPHOSYS AGInventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
-
Patent number: 10913792Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.Type: GrantFiled: January 26, 2018Date of Patent: February 9, 2021Assignee: Morphosys AGInventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
-
Publication number: 20200352975Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.Type: ApplicationFiled: April 3, 2020Publication date: November 12, 2020Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
-
Publication number: 20200353077Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.Type: ApplicationFiled: April 3, 2020Publication date: November 12, 2020Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
-
Publication number: 20200024340Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: June 17, 2019Publication date: January 23, 2020Applicant: MORPHOSYS AGInventors: Stefan Steidl, Elisabeth THOMASSEN-WOLF
-
Patent number: 10377820Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: December 21, 2016Date of Patent: August 13, 2019Assignee: Morphosys AGInventors: Stefan Steidl, Elisabeth Thomassen-Wolf
-
Publication number: 20180258181Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 5, 2018Publication date: September 13, 2018Applicant: Bayer Intellectual Property GmbHInventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
-
Publication number: 20180237531Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: April 17, 2018Publication date: August 23, 2018Inventors: Stefan STEIDL, John Allan HAMILTON, Andrew David COOK
-
Publication number: 20180230208Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.Type: ApplicationFiled: January 26, 2018Publication date: August 16, 2018Applicant: Morphosys AgInventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
-
Patent number: 10005840Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: GrantFiled: December 16, 2015Date of Patent: June 26, 2018Assignees: MORPHOSYS AG, THE UNIVERSITY OF MELBOURNEInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Patent number: 9751939Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: September 16, 2010Date of Patent: September 5, 2017Assignee: Morphosys AGInventors: Stefan Steidl, Elisabeth Thomassen-Wolf
-
Publication number: 20170218061Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: December 21, 2016Publication date: August 3, 2017Applicant: MORPHOSYS AGInventors: Stefan Steidl, Elisabeth Thomassen-Wolf
-
Publication number: 20160185867Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: ApplicationFiled: December 16, 2015Publication date: June 30, 2016Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Patent number: 9243066Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.Type: GrantFiled: July 17, 2012Date of Patent: January 26, 2016Assignees: University of Melbourne, Morpho Sys AGInventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
-
Publication number: 20150259433Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: March 11, 2015Publication date: September 17, 2015Inventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT